96. Crohn disease Clinical trials / Disease details

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02852694 (ClinicalTrials.gov)	February 28, 2017	9/6/2016	Reduce Risk for Crohn's Disease Patients	Risk-stratified Randomized Controlled Trial in Paediatric Crohn Disease:Methotrexate vs Azathioprine or Adalimumab for Maintaining Remission in Patients at Low or High Risk for Aggressive Disease Course, respectively-a Treatment Strategy	Crohn's Disease	Drug: Methotrexate;Drug: Adalimumab;Drug: Azathioprine / 6 Mercaptopurine	PIBD-Net	European Commission	Recruiting	6 Years	17 Years	All	312	Phase 4	France
2	NCT02413047 (ClinicalTrials.gov)	May 2015	6/3/2015	Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator	A Pilot Study to Evaluate if Response to Infliximab or Adalimumab May be Regained With the Addition of an Immunomodulator	Inflammatory Bowel Disease;Ulcerative Colitis;Crohn's Disease	Drug: Azathioprine;Drug: 6 mercaptopurine;Drug: Methotrexate	Indiana University	NULL	Terminated	18 Years	80 Years	All	3	N/A	United States
3	NCT01629628 (ClinicalTrials.gov)	July 2012	19/6/2012	Adalimumab for the Management of Post-operative Crohn's Disease (CD)	An Investigator Initiated Prospective, Single Center, Randomized, Open Label Study to Assess the Efficacy of Adalimumab for the Maintenance of Remission in Post-operative CD Patients	Crohn Disease	Drug: Adalimumab;Drug: 6 Mercaptopurine	Tel-Aviv Sourasky Medical Center	Abbott	Not yet recruiting	18 Years	70 Years	Both	100	Phase 3	Israel
4	NCT01094613 (ClinicalTrials.gov)	November 2010	25/3/2010	Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease	MultiCTR Randomized Double-Blind Double-Dummy Study to Evaluate Clinical Efficacy/Safety of DR 6MP for Targeted Ileal Delivery vs Purinethol in Patients w/Moderately Active Crohn's Disease	Crohn's Disease	Drug: Delayed Release 6 mercaptopurine;Drug: 6 Mercaptopurine	Teva GTC	NULL	Terminated	18 Years	75 Years	Both	70	Phase 1/Phase 2	Israel
5	NCT00774982 (ClinicalTrials.gov)	December 2008	16/10/2008	Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients	Pilot, Randomized, Open-Label, Two-Way Crossover Comparative Bioavailability Study of 40 mg Delayed Release Oral 6Mercaptopurine Versus 100 mg Purinethol in Patients With Crohns Disease	Crohns Disease	Drug: Delayed Release 6 mercaptopurine;Drug: 6 Mercaptopurine	Teva GTC	NULL	Completed	18 Years	50 Years	Both	12	Phase 1	Israel